Close
Help





JOURNAL

Breast Cancer: Basic and Clinical Research

Everolimus in the Treatment of Metastatic Breast Cancer

Submit a Paper


Breast Cancer: Basic and Clinical Research 2015:9 73-79

Review

Published on 06 Sep 2015

DOI: 10.4137/BCBCR.S29268


Further metadata provided in PDF



Sign up for email alerts to receive notifications of new articles published in Breast Cancer: Basic and Clinical Research

Abstract

The discovery of the mammalian target of rapamycin (mTOR) molecular pathway has brought insight into its vital role in breast cancer pathogenesis. Several clinical trials have shown that the mTOR inhibitor everolimus could improve patient outcomes in several subtypes of breast cancer, including hormone receptor–positive, human epidermal growth factor receptor–negative metastatic disease that has progressed after prior endocrine therapy. This review summarizes findings from clinical trials that have demonstrated the benefit of everolimus in metastatic breast cancer and highlights some new research directions utilizing everolimus.



Downloads

PDF  (2.27 MB PDF FORMAT)

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)

XML





Quick Links


New article and journal news notification services